systematic therapy
PreclinicalSmall molecule
systematic therapy is one of 54 small molecule programs targeting Gastric Cancer. It is currently in Preclinical.
2
Indications
2
Total Trials
1
Active Trials
53
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
193 competitors in Gastric Cancer
#DrugCompanyPhaseTrials
1Taxol
TevaPhase 3
Platinol
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Phase 3
Taxotere
AAvyxa
Phase 3
Cyramza
Eli LillyPhase 3
Tuoyi
SSun Yat-sen University
Phase 3
Yervoy
Bristol-Myers SquibbPhase 3
Adrucil
EElorac, Inc.
Phase 3
S-1
Taiho Oncology, Inc.Phase 3
Apatinib
LLaNova Medicines Zhejiang Co., Ltd.
Phase 3
Apatinib Mesylate
BBukwang Pharmaceutical
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Leptomeningeal Metastasis1 trial
Development of a Novel Graded Prognostic Assessment (BC-LGPA) Model for Breast Cancer Leptomeningeal Metastasis
Completed·—··NCT07386886·403 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for systematic therapy. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- PPeking University Third Hospital